CN111093652A - 使用丹曲林治疗神经毒剂暴露的方法 - Google Patents

使用丹曲林治疗神经毒剂暴露的方法 Download PDF

Info

Publication number
CN111093652A
CN111093652A CN201880057290.XA CN201880057290A CN111093652A CN 111093652 A CN111093652 A CN 111093652A CN 201880057290 A CN201880057290 A CN 201880057290A CN 111093652 A CN111093652 A CN 111093652A
Authority
CN
China
Prior art keywords
dantrolene
subject
pharmaceutical composition
nerve agent
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880057290.XA
Other languages
English (en)
Chinese (zh)
Inventor
阿德里安·赫普纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eagle Pharmaceuticals Inc
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of CN111093652A publication Critical patent/CN111093652A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201880057290.XA 2017-09-05 2018-09-05 使用丹曲林治疗神经毒剂暴露的方法 Pending CN111093652A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762554049P 2017-09-05 2017-09-05
US62/554,049 2017-09-05
US201862674406P 2018-05-21 2018-05-21
US62/674,406 2018-05-21
PCT/US2018/049515 WO2019050923A1 (en) 2017-09-05 2018-09-05 METHODS OF USING DANTROLENE TO TREAT EXPOSURE TO A NEUROTOXIC AGENT

Publications (1)

Publication Number Publication Date
CN111093652A true CN111093652A (zh) 2020-05-01

Family

ID=63708449

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880057290.XA Pending CN111093652A (zh) 2017-09-05 2018-09-05 使用丹曲林治疗神经毒剂暴露的方法

Country Status (15)

Country Link
US (2) US20200383954A1 (https=)
EP (1) EP3678659B1 (https=)
JP (2) JP2020532555A (https=)
KR (1) KR20200047655A (https=)
CN (1) CN111093652A (https=)
AU (1) AU2018328131B2 (https=)
BR (1) BR112020004429A2 (https=)
CA (1) CA3074732A1 (https=)
IL (1) IL272847B1 (https=)
MA (1) MA50080A (https=)
MX (2) MX2020002485A (https=)
SG (1) SG11202001749SA (https=)
UA (1) UA126688C2 (https=)
WO (1) WO2019050923A1 (https=)
ZA (1) ZA202001258B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538608A (ja) * 2019-06-28 2022-09-05 ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア アルツハイマー病の治療のための鼻腔内ダントロレン投与
WO2023081873A1 (en) * 2021-11-05 2023-05-11 Quorum Innovations, Llc Materials and methods for preventing or reducing toxicity to organophosphates and other toxic materials

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242646A1 (en) * 2001-06-23 2004-12-02 Anderson David M. Treatment using dantrolene
US20130071394A1 (en) * 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603513B1 (en) * 2003-03-04 2020-12-30 Lyotropic Therapeutics, Inc. Dantrolene compositions
DK2925327T3 (da) * 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242646A1 (en) * 2001-06-23 2004-12-02 Anderson David M. Treatment using dantrolene
US20130071394A1 (en) * 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. FILBERT等: "A viable neuroprotection strategy following soman-induced status epilepticus", 《美国政府科技报告》 *
SD TUORINSKY等: "《Medical Aspects of Chemical Warfare》", 31 December 2008 *

Also Published As

Publication number Publication date
JP2023055802A (ja) 2023-04-18
EP3678659C0 (en) 2025-12-17
MX2020002485A (es) 2020-07-20
SG11202001749SA (en) 2020-03-30
BR112020004429A2 (pt) 2020-10-20
RU2020112318A (ru) 2021-10-06
NZ762056A (en) 2025-10-31
JP2020532555A (ja) 2020-11-12
AU2018328131B2 (en) 2024-04-18
US20200383954A1 (en) 2020-12-10
EP3678659A1 (en) 2020-07-15
UA126688C2 (uk) 2023-01-11
MA50080A (fr) 2020-07-15
IL272847B1 (en) 2026-03-01
MX2023012415A (es) 2023-11-01
CA3074732A1 (en) 2019-03-14
US20220087980A1 (en) 2022-03-24
AU2018328131A1 (en) 2020-03-12
ZA202001258B (en) 2023-10-25
RU2020112318A3 (https=) 2021-10-26
EP3678659B1 (en) 2025-12-17
IL272847A (en) 2020-04-30
WO2019050923A1 (en) 2019-03-14
KR20200047655A (ko) 2020-05-07

Similar Documents

Publication Publication Date Title
Shih et al. Anticonvulsants for nerve agent-induced seizures: the influence of the therapeutic dose of atropine
EP1113797B1 (en) Use of duloxetine for the treatment of fibromyalgia
CN102657664A (zh) 用于治疗疼痛和其它α2肾上腺素能介导疾病的方法及组合物
WO2000003713A1 (en) Treatment for schizophrenia and other dopamine system dysfunctions
US20210085749A1 (en) Therapeutic and Neuroprotective Peptides
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
Schultz et al. The anticholinergic and antiglutamatergic drug caramiphen reduces seizure duration in soman-exposed rats: synergism with the benzodiazepine diazepam
US20260022144A1 (en) Analgesic polypeptide
JP2023055802A (ja) ダントロレンを使用して神経薬暴露を治療する方法
JP2025108527A (ja) 化学的除神経から生じる副作用の処置
Marrs The role of diazepam in the treatment of nerve agent poisoning in a civilian population
WO2011029082A1 (en) Durable treatment with 4-aminopyridine in patients with demyelination
EP0414568A2 (en) Use of anticholinergic compounds for protecting the central nervous system against cholinergic neurotoxins
Thomas et al. In vivo evaluation of a1 adenosine agonists as novel anticonvulsant medical countermeasures to nerve agent intoxication in a rat soman seizure model
US20040192699A1 (en) Optic nerve protecting agents containing alpha1 receptor blocker as active ingredient
US10806741B2 (en) Treatments for free-living amoebic infections
Sinha et al. Organophosphate poisoning: A review
RU2817851C2 (ru) Способы применения дантролена для лечения воздействия нервно-паралитического вещества
Nekoukar et al. Management of organophosphorus poisoning and the role of magnesium sulfate: A scoping review of literature.
Ivosevic et al. Mechanism and clinical importance of respiratory failure induced by anticholinesterases
Thomas et al. Pharmacological Evaluation of Candidate Adenosine Agonists as Novel Anticonvulsant Medical Countermeasures to Soman Nerve Agent Intoxication
Amrithachandra et al. Killer Secretions: Organophosphorus Poisoning: Practice Eessentials and Protocols
US10398687B2 (en) Use of cyproheptadine to treat organophosphate exposure
JP2022552162A (ja) 物質使用障害の処置のための１８－ｍｃ
Nekoukar et al. The key role of magnesium sulfate in the management of organophosphorus pesticide poisoning: a scoping literature

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200501